2022-502275-39-00Active, not recruitingPhase 1/2
A phase 1/phase 2 study to investigate safety, tolerability and efficacy with TG01/QS-21 vaccine administration in patients with confirmed KRAS or NRAS codon 12/13 mutation and high-risk smoldering multiple myeloma or multiple myeloma and evidence of measurable disease ≥ 1 line of treatment.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 11 Jun 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 20 Oct 2022
- Start date
- 19 May 2023
- Lead sponsor
- Oslo University Hospital Hf
- Diseases
- Multiple myeloma
- EU CT number
- 2022-502275-39-00
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 20
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oslo University Hospital HF | Oslo | Norway | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.